Since the discovery of THC, the medical industry has been interested in studying the interactions between cannabinoids and the human endocannabinoid system (ECS). Synthetic cannabinoids (SCBs) have been developed to mimic the effects of natural cannabinoids, with thousands of compounds created. These chemicals have different structures and a higher affinity for ECS receptors, making them more potent than natural cannabinoids. They have been used in pharmacological studies and show potential for treating various medical conditions. However, they also have drawbacks such as unpredictable side effects and a higher risk for abuse.
Biotechnology has a long history and has revolutionized many fields, including medicine, agriculture, and industrial manufacturing. In the cannabis industry, researchers are exploiting biotechnological advances to unlock the plant’s potential. One application of biotechnology to cannabis is the genetic engineering of plants to produce crops with enhanced characteristics, including a higher CBD/THC ratio or no THC. […]
CBD and THC are the two most significant cannabinoids found in cannabis. Raphael Mechoulam discovered the structure of THC in 1964 and found it to be psychoactive. The discovery of THC led to the exploration of the endocannabinoid system (ECS) which is made up of chemical compounds that bind to cannabinoid receptors (CBRs) found in the nervous system. The ECS influences a wide variety of processes, including motor learning, appetite, and pain sensation. THC is thought to bind to CB1 receptors in the brain and regulate hunger by affecting the production of endocannabinoids.